U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
19. Dezember 2024 14:58 ET
|
Zealand Pharma
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
10. Dezember 2024 09:00 ET
|
Zealand Pharma
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the...
Zealand Pharma to participate in the Jefferies London Healthcare Conference
13. November 2024 12:00 ET
|
Zealand Pharma
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078),...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
11. November 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
07. November 2024 01:00 ET
|
Zealand Pharma
Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for...
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
01. November 2024 12:30 ET
|
Zealand Pharma
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1,...
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
08. Oktober 2024 18:45 ET
|
Zealand Pharma
Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response...
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
08. Oktober 2024 02:40 ET
|
Zealand Pharma
Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide ...
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
30. September 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
13. September 2024 11:01 ET
|
Zealand Pharma
Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S...